When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
LGND - Ligand Pharmaceuticals EPS beats by $0.27 beats on revenue; updates full year guidance
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals (NASDAQ:LGND): Q2 Non-GAAP EPS of $1.63 beats by $0.27; GAAP EPS of $1.79 beats by $1.05. Revenue of $84.7M (+104.5% Y/Y) beats by $13.29M. Ligand now expects full-year 2021 total revenues to be between $265 million and $275 million (prior $291 million) vs. consensus of $276.63M , and adjusted earnings per diluted share to be between $5.80 and $6.05 (prior $6.15) vs. consensus of $3.79. Press Release